About Us

Nail Genesis is a subsidiary of Chesson Labs seeking investments to fund a premarket approval (PMA) clinical trial for a topical prescription onychomycosis (nail fungus) product. The incorporation of Nail Genesis allows for a clear differentiation from Chesson Labs’ over-the-counter wound care products and the development of this prescription onychomycosis product. 

INVESTMENT STRUCTURE

MARKET NEED AND SOLUTION

MARKET NEED AND SOLUTION

The minimum individual investment is $50K. The funding round will cover the entire cost of a multicenter, randomized, controlled clinical trial, and a PMA application submission to the FDA.

MARKET NEED AND SOLUTION

MARKET NEED AND SOLUTION

MARKET NEED AND SOLUTION

Onychomycosis is a nail fungal infection that affects up to 40 million adults in the U.S. Onychomycosis causes discoloration, thickening, and separation from the nail bed especially in toenails. The disease can lead to severe pain and can hamper an individual’s work and social life. Nail Genesis’s product is a proven topical polymer that demonstrated high efficacy in a feasibility study.

The onychomycosis market is growing at almost 10% CAGR, $1.8B US market (70% topical). 

INVESTMENT SUMMARY

The product will be the first topical Rx medical device on the market and will have the same indication for use and comparator data as current Rx drug products. The product has proven efficacy and safety profiles and multiple patents. The licensee/acquirer company target list is continually growing.
-

The product has a low risk profile with a compelling upside market opportunity and has the potential to be a $100M-plus product in annual revenue. 

Contact Us

Scott E. Neuville President and CEO, Chesson Labs mobile: (919) 349-3747 sneuville@chessonlabs.com

Nail Genesis

A subsidiary of Chesson Labs

Copyright © 2023 Nail Genesis - All Rights Reserved.